Abstract
Background: Overall survival in hepatocellular carcinoma patients treated with percutaneous radiofrequency ablation is influenced by both recurrence and successive treatments. We investigated post-recurrence survival after radiofrequency ablation. Methods: Data on 103 early/intermediate patients initially treated with radiofrequency ablation and followed for a median of 78 months (range 68-82) were retrospectively analysed. If intrahepatic disease recurrence occurred within or contiguous to the previously treated area it was defined as local, otherwise as distant; recurrence classified as Barcelona Clinic Liver Cancer stage C was defined by neoplastic portal vein thrombosis or metastases. Results: A total of 103 patients were included (82.5% male, median age 70 years, range 39-86). During follow-up, 64 recurrences were observed. Median overall survival was 62 months (95% confidence interval: 54-78) and survival rates were 97%, 65% and 52% at 1, 4 and 5 years, respectively. Median post-recurrence survival was 22 months (95% confidence interval: 16-35). Child-Pugh score, performance status, sum of tumour diameters at recurrence and recurrence patterns were independent predictors of post-recurrence survival. Conclusions: In patients with hepatocellular carcinoma after radiofrequency ablation, clinical and tumour parameters assessed at relapse, in particular the type of recurrence pattern, influence post-recurrence survival.
| Original language | English |
|---|---|
| Pages (from-to) | 1014-1019 |
| Number of pages | 6 |
| Journal | Digestive and Liver Disease |
| Volume | 46 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 1 2014 |
Fingerprint
Keywords
- HCC
- Liver cancer
- PRS
- RFA
ASJC Scopus subject areas
- Gastroenterology
- Hepatology
- Medicine(all)
Cite this
Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation. / Facciorusso, Antonio; Del Prete, Valentina; Antonino, Matteo; Crucinio, Nicola; Neve, Viviana; Di Leo, Alfredo; Carr, Brian I.; Barone, Michele.
In: Digestive and Liver Disease, Vol. 46, No. 11, 01.11.2014, p. 1014-1019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Post-recurrence survival in hepatocellular carcinoma after percutaneous radiofrequency ablation
AU - Facciorusso, Antonio
AU - Del Prete, Valentina
AU - Antonino, Matteo
AU - Crucinio, Nicola
AU - Neve, Viviana
AU - Di Leo, Alfredo
AU - Carr, Brian I.
AU - Barone, Michele
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Background: Overall survival in hepatocellular carcinoma patients treated with percutaneous radiofrequency ablation is influenced by both recurrence and successive treatments. We investigated post-recurrence survival after radiofrequency ablation. Methods: Data on 103 early/intermediate patients initially treated with radiofrequency ablation and followed for a median of 78 months (range 68-82) were retrospectively analysed. If intrahepatic disease recurrence occurred within or contiguous to the previously treated area it was defined as local, otherwise as distant; recurrence classified as Barcelona Clinic Liver Cancer stage C was defined by neoplastic portal vein thrombosis or metastases. Results: A total of 103 patients were included (82.5% male, median age 70 years, range 39-86). During follow-up, 64 recurrences were observed. Median overall survival was 62 months (95% confidence interval: 54-78) and survival rates were 97%, 65% and 52% at 1, 4 and 5 years, respectively. Median post-recurrence survival was 22 months (95% confidence interval: 16-35). Child-Pugh score, performance status, sum of tumour diameters at recurrence and recurrence patterns were independent predictors of post-recurrence survival. Conclusions: In patients with hepatocellular carcinoma after radiofrequency ablation, clinical and tumour parameters assessed at relapse, in particular the type of recurrence pattern, influence post-recurrence survival.
AB - Background: Overall survival in hepatocellular carcinoma patients treated with percutaneous radiofrequency ablation is influenced by both recurrence and successive treatments. We investigated post-recurrence survival after radiofrequency ablation. Methods: Data on 103 early/intermediate patients initially treated with radiofrequency ablation and followed for a median of 78 months (range 68-82) were retrospectively analysed. If intrahepatic disease recurrence occurred within or contiguous to the previously treated area it was defined as local, otherwise as distant; recurrence classified as Barcelona Clinic Liver Cancer stage C was defined by neoplastic portal vein thrombosis or metastases. Results: A total of 103 patients were included (82.5% male, median age 70 years, range 39-86). During follow-up, 64 recurrences were observed. Median overall survival was 62 months (95% confidence interval: 54-78) and survival rates were 97%, 65% and 52% at 1, 4 and 5 years, respectively. Median post-recurrence survival was 22 months (95% confidence interval: 16-35). Child-Pugh score, performance status, sum of tumour diameters at recurrence and recurrence patterns were independent predictors of post-recurrence survival. Conclusions: In patients with hepatocellular carcinoma after radiofrequency ablation, clinical and tumour parameters assessed at relapse, in particular the type of recurrence pattern, influence post-recurrence survival.
KW - HCC
KW - Liver cancer
KW - PRS
KW - RFA
UR - http://www.scopus.com/inward/record.url?scp=84908241374&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908241374&partnerID=8YFLogxK
U2 - 10.1016/j.dld.2014.07.012
DO - 10.1016/j.dld.2014.07.012
M3 - Article
C2 - 25085684
AN - SCOPUS:84908241374
VL - 46
SP - 1014
EP - 1019
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
SN - 1590-8658
IS - 11
ER -